These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31434110)

  • 1. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    Rajagopal PS; Nielsen S; Olopade OI
    JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
    [No Abstract]   [Full Text] [Related]  

  • 2. USPSTF recommends BRCA testing in women based on familial history.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E6. PubMed ID: 25618620
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
    Finch AP; Lubinski J; Møller P; Singer CF; Karlan B; Senter L; Rosen B; Maehle L; Ghadirian P; Cybulski C; Huzarski T; Eisen A; Foulkes WD; Kim-Sing C; Ainsworth P; Tung N; Lynch HT; Neuhausen S; Metcalfe KA; Thompson I; Murphy J; Sun P; Narod SA
    J Clin Oncol; 2014 May; 32(15):1547-53. PubMed ID: 24567435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
    Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
    Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma.
    Novetsky AP; Smith K; Babb SA; Jeffe DB; Hagemann AR; Thaker PH; Powell MA; Mutch DG; Massad LS; Zighelboim I
    Int J Gynecol Cancer; 2013 Jul; 23(6):1016-21. PubMed ID: 23748176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
    Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
    Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?
    Powell CB; Littell R; Hoodfar E; Sinclair F; Pressman A
    Int J Gynecol Cancer; 2013 Mar; 23(3):431-6. PubMed ID: 23354368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposal on Raloxifene use after prophylactic salpingo-oophorectomy in BRCA1-2: hypothesis and rationale.
    Gizzo S; Noventa M; Saccardi C; Litta P; D'Antona D; Nardelli GB
    Eur J Cancer Prev; 2014 Nov; 23(6):514-5. PubMed ID: 25254310
    [No Abstract]   [Full Text] [Related]  

  • 16. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    Levy-Lahad E; Lahad A; King MC
    J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
    Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
    Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
    J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.